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CASE PRESENTATION
A 63-year-old woman of South Asian origin, a
Gujerati-speaking Hindu, was admitted 5 years ago to the
renal unit at Leicester General Hospital for further eval-
uation of chronic kidney disease (CKD). She was born
in India, moved to East Africa as a child, and migrated
from Malawi to the United Kingdom in 1972. Her medi-
cal history included four uneventful pregnancies. She has
no history of diabetes mellitus or hypertension. Three of
her cousins had developed type 2 diabetes in the fourth
decade of life, and her deceased aunt developed end-stage
renal disease (ESRD) in the seventh decade of life and
required renal replacement therapy (RRT).
Three months before admission, the patient had re-
ported increasing tiredness and was found to have a nor-
mochromic normocytic anemia, which was unresponsive
to oral iron supplementation. On admission she reported
continuing tiredness and breathlessness on moderate ex-
ertion, with no angina, cough, sputum, or wheeze. She
reported nocturia for the previous 5 years but no other
urinary symptoms. A review of systems was otherwise
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unremarkable. She was a vegetarian, a non-smoker, and
she drank no alcohol.
On examination she was clinically anemic and over-
weight [body mass index (BMI), 31 kg/m2]. Her blood
pressure was 145/90 mm Hg, the cardiovascular exami-
nation was otherwise normal, and all peripheral pulses
were preserved with no bruits. The lung fields were clear.
Abdominal examination revealed no masses, and the
pelvic examination was normal. She had a waddling gait.
Laboratory investigations revealed hemoglobin, 8.9 g/dL;
mean corpuscular volume, 90 fl; white blood cell count,
4.3 × 109/L with normal differential; ferritin, 53 lg/L;
C-reactive protein (CRP), <5 mg/L; plasma sodium,
135 mmol/L; potassium, 5.0 mmol/L; urea, 21 mmol/L
[blood urea nitrogen (BUN), 59 mg/dL); serum cre-
atinine, 345 mol/L (3.9 mg/dL); estimated glomerular
filtration rate (GFR), 19 mL/min; serum bicarbonate,
15 mmol/L; albumin, 35 g/L; total protein, 74 g/L; serum
calcium, 1.9 mmol/L; phosphate, 1.9 mmol/L; alkaline
phosphatase, 326 IU/L; serum 25-OH vitamin D3, 6 IU/L;
and intact parathyroid hormone (iPTH), 42 pmol/L. Au-
toantibody screen and serologic tests for lupus were nor-
mal. An ultrasound scan showed symmetrical shrunken
kidneys (7 cm bipolar length) with smooth outlines and
no evidence of stones or hydronephrosis. Urinalysis dis-
closed 1+ protein, no blood, and a bland urine sediment
with only occasional hyaline casts. The urine albumin-to-
creatinine ratio was 15 mg/mmol.
Initial treatment included oral sodium bicarbon-
ate supplementation. Blood pressure was controlled
at 130/80 mm Hg with atenolol and amlodipine.
Hemoglobin was corrected to 11.5 g/dL with intravenous
iron and subcutaneous erythropoietin. Serum calcium
and phosphate were controlled with dietary modifica-
tion, calcium carbonate, and alfacalcidol. Her renal func-
tion steadily deteriorated, and 3 months after initial eval-
uation she was established on continuous ambulatory
peritoneal dialysis (CAPD). Within 6 months, technique
failure was associated with recurrent peritonitis. She was
established on regular hemodialysis (HD) with a right in-
ternal jugular PermCath followed by three unsuccessful
attempts to establish an arteriovenous fistula sufficient
for regular dialysis. One year after dialysis was initiated,
she received a living-related renal transplant from her
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son. Transplantation was unremarkable and the graft
functioned immediately. Three years later, she is well
with excellent graft function [serum creatinine, 88 mol/L
(1.0 mg/dL)] and she takes prednisolone and tacrolimus
for maintenance immunosuppression.
DISCUSSION
PROFESSIR JOHN FEEHALLY (The John Walls Renal
Unit, Leicester General Hospital, Leicester, United King-
dom): People from indigenous or migrant ethnic minor-
ity populations have increased susceptibility to CKD, and
the woman whose case is discussed here is in many ways
typical. She first presented to the renal service with ad-
vanced CKD of undeterminable cause and a family his-
tory of CKD and type 2 diabetes, although the patient
herself is not diabetic. She was already anemic and aci-
dotic, had metabolic bone disease, and soon required
RRT. After periods on peritoneal dialysis (PD) and HD
with considerable technical challenges, she received a suc-
cessful kidney transplant from a living-related donor.
As well as the challenges of understanding and revers-
ing the epidemic of CKD exemplified by this woman,
there are major public health implications in delivering
the increased demands for RRT in areas serving minority
populations. In this Nephrology Forum, I shall review our
current knowledge of the epidemiology of CKD in eth-
nic minority populations, the likely pathogenetic mech-
anisms underlying the epidemic, the interventions likely
to detect and reduce the epidemic, as well as the pub-
lic health implications of the increased demand for RRT.
I shall focus in particular on emerging evidence in the
United Kingdom but shall also maintain an international
perspective.
Epidemiology
The migration of ethnic minority populations to the
United Kingdom has occurred rapidly in the last half-
century and continues to accelerate. A sharp increase in
the African Caribbean population in the United King-
dom started in the 1950s; then a rapid migration of South
Asians occurred in the early 1970s from sub-Saharan
Africa when political change created insecurity for a large
South Asian population originally migrant from the In-
dian subcontinent. Recently a more diffuse migration has
gained momentum, particularly from a number of other
African populations. The ethnic minority population in
the United Kingdom continues to grow and now com-
prises 8% of the general population. For example, in the
1991 census, South Asians were 8.4% of the Leicester-
shire population, but 22% of those living within the city
boundary of Leicester. By the time of the 2001 census,
more than 50% of those living within the Leicester city
boundary were of South Asian origin (the term South
Asian applies to people originating from the Indian sub-
continent and includes people from a wide range of cul-
tural and religious heritages, including Hindus, Sikhs, and
Muslims, and the term Asian describes people originat-
ing from China, Japan, and other countries on the west-
ern Pacific Rim). All such migrations bring with them
challenges to health care. Even if migrant populations
had no variations in disease susceptibility, substantial lan-
guage and cultural variations would provide additional
demands on the health care system. In fact, disease vari-
ations in the United Kingdom’s South Asian population
include marked increases in susceptibility to type 2 di-
abetes, coronary heart disease, and CKD [1, 2]. African
Caribbeans have an additional susceptibility to severe hy-
pertension and the subsequent end organ damage. The
South Asian population in the United Kingdom also has
a younger age distribution than the indigenous white pop-
ulation, so that diseases such as CKD, which increase
in incidence with increasing age, will at first be under-
represented compared to the eventual population burden
as the minority population ages.
Worldwide epidemiologic evidence indicates that the
incidence of CKD is increased in many ethnic minority
populations. Most studies have used the onset of ESRD
and acceptance for RRT as a means of case ascertain-
ment, but this approach might underestimate the true in-
cidence if patients have inequity of access to RRT. There
a is three- to fourfold increase in the incidence of ESRD
in South Asian and African Caribbean populations in the
United Kingdom [2, 3], and there are similar increases in
African Americans, Hispanics, and Native Americans in
the United States [4, 5]. Other populations at increased
risk include Aborigines, Maoris, and Pacific Islanders in
Australasia.
It is common for us to emphasize the increased sus-
ceptibility to ESRD in these ethnic minority populations.
But perhaps we should instead consider that the white
European population is uniquely at low risk of renal dis-
ease. This decreased risk could be due to genetic reasons,
or because in most white populations, the environmen-
tal changes of urbanization were imposed so much more
slowly.
In more homogeneous populations, the incidence of
ESRD is even more strikingly increased. Members of the
Native American Pima tribe have a specific susceptibility
to diabetic nephropathy [6], whereas Native Americans
of the Zuni Pueblo tribe, with an incidence of ESRD 18
times that of white Americans, have a broader susceptibil-
ity to CKD as well as diabetic nephropathy and glomeru-
lonephritis [7]. The Aboriginal population in Tiwi Island,
Northern Territory, where obesity and type 2 diabetes are
endemic, has an ESRD incidence more than 2000/million
population/year; comprising only 26% of the population
of Northern Territory, Aborigines are 96% of those on
RRT [8].
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All these ethnic minority populations at increased risk
of CKD share a marked increase in susceptibility to type
2 diabetes, with an increased susceptibility among diabet-
ics to ESRD. For example, data from Leicester indicated
a 13-fold increase in the risk of a South Asian diabetic
developing ESRD compared to a white diabetic [9], the
Pima Indians have a risk of ESRD 14 times that of the
white United States population [10], and there is also a
marked increase in African American type 2 diabetics
compared to whites. Current predictions suggest an in-
crease in the prevalence of type 2 diabetes of 30% to
50% above current levels by the year 2025 in developed
countries, but two- to threefold increases in prevalence
in developing countries during the same period [11]. This
predicted epidemic of ESRD in people with diabetes will
be uncontainable unless effective preventive strategies
are developed.
As well as susceptibility to diabetic ESRD, the other
major cause of ESRD in the black population is hyperten-
sion. Other causes of ESRD have been less well studied,
but data from Leicester and Hammersmith Hospital also
indicate increases in the incidence of glomerulonephritis
as well as reflux nephropathy in South Asians [2]. Further-
more there is an excess of patients in whom the cause
of renal disease is not identified; they typically present
with advanced renal impairment, bland urine findings,
and shrunken kidneys on renal imaging and thus do not
undergo renal biopsy [2]. A more recent study confirms
the wide range of renal pathology that is increased in the
South Asian population and suggests that a substantial
proportion of those cases of undetermined cause consti-
tute chronic tubulointerstitial nephritis (TIN). The causes
of the TIN have not been elucidated [12]. Corticosteroid
therapy has been used with some benefit, although this
approach has not been rigorously studied. Sporadic evi-
dence suggests that tuberculosis is sometimes an etiologic
agent; centers treating such South Asian populations typ-
ically identify a small number of such patients whose renal
function improves in response to antituberculous treat-
ment [13].
Studies using requirement for RRT for case ascertain-
ment will not distinguish susceptibility to the develop-
ment of renal disease from an increased risk of progres-
sion to ESRD once nephropathy is established. In hy-
pertensive blacks, there is long-established evidence of
increased progression risk despite equivalent blood pres-
sure control [14]. In CKD of other etiologies, evidence
increasingly points to the increased risk of progression
as the predominant explanation for increased ESRD. A
United States birth cohort analysis showed no difference
between blacks and whites in the prevalence of CKD, yet
5 years later in the same cohort, a near fivefold increased
risk of ESRD among the blacks was apparent [15]. Re-
cent screening data from London also show no difference
in the prevalence of early CKD between white and South
Asian populations despite the marked excess of ESRD in
South Asians [Lightstone L, unpublished observations].
The Australian Aborigines in Tiwi Island have the un-
enviable reputation of being among the least healthy peo-
ple in the world. The high incidence of ESRD as well as
endemic obesity and type 2 diabetes are associated with
a standardized mortality ratio more than four times that
of whites living in the same area and a sixfold increase in
cardiovascular deaths [16]. This is a potent reminder that
ESRD carries with it more risks than merely the conse-
quences of lifelong RRT. Accelerated cardiovascular dis-
ease is the major cause of death in all ESRD populations.
In all populations that have been studied, proteinuria,
even if it has not resulted in renal failure, is an indepen-
dent risk factor for such cardiovascular mortality.
Pathogenesis
Genetic susceptibility to renal diseases and their pro-
gression, susceptibility provoked by environmental fac-
tors, susceptibility induced by the effects of fetal environ-
ment, and socioeconomic influences all can contribute to
susceptibility to CKD in ethnic minority populations [17–
19]. Substantial indirect evidence supports a genetic ba-
sis for susceptibility. This evidence includes the increased
risk of renal disease among the first-degree relatives of
ethnic minority populations with ESRD [20], even when
the confounding variable of consanguinity is taken into
account. The marked increase in susceptibility to dia-
betic nephropathy in the Pima Indians suggests a ge-
netic influence in that population. Genetic evaluation of
the Zuni Indians might prove more informative, because
their broader susceptibility to CKD has more similarity to
the South Asian population. That is, they carry a double
jeopardy not only of susceptibility to type 2 diabetes but
also an independent susceptibility to CKD. The African
Caribbean population likewise has susceptibility to type
2 diabetes, but their renal disease risk is made more com-
plex by the additional susceptibility to end-organ damage
from hypertension [21] and sickle cell disease.
While new approaches to analysis of the human
genome hold out much promise, no genes linked with
susceptibility to CKD have been identified in ethnic mi-
nority populations. Even in a population with as much
apparent homogeneity as the Pima Indians, a genome-
wide search strategy has identified possible susceptibility
loci on four different chromosomal regions [22]. A num-
ber of substantial collections of DNA from probands in
ethnic minority populations with ESRD are being estab-
lished around the world to facilitate genetic studies, for
example, a multi-ethnic cohort of 10,000 probands with
diabetic ESRD in the United States [23]. Even though
epidemiologic data suggest a broad increase in suscepti-
bility to ESRD in South Asians, the enormous cultural,
religious, and social variety among South Asians must be
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recognized. One study in Pakistan indicates that one’s
ethnic subgroup influences the prevalence of proteinuria
[24]. Cohorts assembled for DNA studies therefore must
be of sufficient size and mix to minimize the risk that any
ethnic stratification confounds study findings.
Many racial groups have an increased susceptibility
to renal disease, and this issue has particularly been
explored in the context of type 2 diabetes, as popula-
tions undergo rapid urbanization. One favored hypoth-
esis has been that these populations exhibit a “thrifty
genotype,” [25] which has become dominant through nat-
ural selection, as it confers the capacity to lay down fat
and carbohydrate stores in response to occasional plenty
among prolonged periods of famine, and was therefore
an ideal genotype for survival among hunter-gatherers.
When confronted with sustained plenty, such a genotype,
unless environmentally rigorously controlled, creates sus-
ceptibility to the “metabolic syndrome” (obesity, insulin
resistance, type 2 diabetes, and dyslipidemia), vascular
disease, and with it an increased risk of renal disease. An-
other view favors the existence of a “thrifty phenotype”
in which intra-uterine and early life environments create
an acquired metabolic state adapted for relative starva-
tion but with increased susceptibility to the metabolic
syndrome. However, when social and environmental cir-
cumstances allow increased access to food in childhood
and adult life, “catch-up” weight gain ensues, again re-
sulting in the metabolic syndrome [26, 27]. Identifying the
relative contributions of genetic and environmental influ-
ences is hampered by the relative paucity of population-
based studies for establishing the true incidence of renal
disease in the regions where these migrant populations
originate.
The hypothesis of Barker et al [28] emphasizes the im-
pact of the fetal environment on subsequent adult dis-
ease, proposing that in utero “programming” contributes
to adult disease. The basis of the hypothesis is epidemi-
ologic evidence in the United Kingdom and elsewhere
that low birth weight, due to intra-uterine growth retar-
dation rather than to prematurity, is associated with in-
creased adult risk of type 2 diabetes, insulin resistance,
coronary heart disease, and hypertension, although the
association with hypertension has recently been chal-
lenged [29]. Starvation at puberty might similarly predis-
pose to cardiovascular disease [27]. It is of course difficult
to distinguish between in utero effects and those of sub-
sequent adverse environmental factors that in early life
might be closely associated with the same circumstances
that provoke maternal undernutrition. It is additionally
proposed that low birth weight reduces nephron number
and increases susceptibility to systemic hypertension and
renal disease [30], and there is evidence in whites of a re-
lationship between primary hypertension and nephron
number [31]. Considerable indirect evidence also sug-
gests that in utero programming contributes to adult re-
nal disease. The kidney is particularly susceptible to fetal
malnutrition because 60% of nephrons are formed in the
third trimester; evidence also indicates that kidney size
is disproportionately reduced in babies who are small for
gestational age [32], although there are no data in this
study on ethnicity. Recent autopsy studies also confirm
an association among low birth weight, reduced nephron
number, and increased glomerular size, a factor known
in a variety of experimental studies to increase the risk of
glomerulosclerosis [33, 34]. Evidence exists of increased
glomerular size in African Americans and Pima Indians,
but autopsy studies did not confirm any additional impact
of ethnicity modifying the relationship between glomeru-
lar characteristics and birth weight. Thus, it is low birth
weight per se that likely carries the increased suscepti-
bility. In the Tiwi Island Aborigine population in whom
25% have a birth weight less than 2500 g, a direct associ-
ation exists between low birth weight and increasing risk
of adult proteinuria, and systolic blood pressure and pro-
teinuria are inversely related to kidney length and volume
[35].
Finally, powerful evidence indicates that socioeco-
nomic disadvantage is associated with increased risk of
ESRD [18, 36], a complex interaction that might directly
influence renal damage, be associated with damaging
health behaviors, or influence the quality of health care
of those with kidney disease.
Effective interventions
The Barker hypothesis suggests that reductions in in-
fant mortality since the 1960s in many parts of the world
will result in the survival to adult life of large cohorts of
low-birth-weight infants at risk of renal and other chronic
diseases. This phenomenon should abate if birth weights
continue to increase.
General population screening for hypertension and di-
abetes, followed by their effective early management, are
well established strategies that will reduce both cardio-
vascular risk and the risk of CKD. Screening for CKD
has never been advocated in the United Kingdom; al-
though the costs and implications of progressive CKD are
substantial, its relative rarity has never been considered
as justifying population-wide screening. Although only
moderate systematic evidence supports screening, the
International Society of Nephrology recently advocated
screening of high-risk populations in developed coun-
tries, including ethnic minority populations (www.isn-
online.org). Which screening tools are most appropriate
remains under investigation. The prime justification for
screening is that earlier intervention can delay or pre-
vent the onset of renal failure. It is proposed that nearly
one-half of the excess ESRD risk in African Americans
can be explained on the basis of potentially modifiable
risk factors [37]. Powerful evidence suggests that tight
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blood pressure control is a highly effective strategy for
slowing progression of CKD, and when proteinuria is
present, therapy should comprise blockade of the renin-
angiotensin system (RAS) by angiotensin-converting en-
zyme (ACE) inhibitors or angiotensin-receptor blockers
(ARBs) or perhaps by an ACE inhibitor and ARB in
combination. Little evidence suggests that unique strate-
gies are required to minimize the progression of CKD in
ethnic minority populations [38]. No known unique risk
factors suggest that information from clinical trials should
be applied differently in these populations. Studies show-
ing benefits of renin-angiotensin blockade in diabetic and
non-diabetic proteinuric nephropathy have been under-
taken predominantly in whites, but the African Ameri-
can Study of Kidney Disease and Hypertension (AASK)
study clearly shows the benefits of including an ACE in-
hibitor in the treatment regimen when proteinuria ex-
ceeds as little as 300 mg/24 hours [39]. Poor control of
risk factors for CKD is universal, and the challenge is
developing approaches that ensure a wide application of
lifestyle changes, equitable access to health care that is
culturally specific, and best clinical practice in all popu-
lation settings.
Encouraging evidence from the very high risk Aus-
tralian Aboriginal population in Tiwi Island suggests that
these goals can be achieved. A community-based study
identified high-risk patients (blood pressure > 140/90 mm
Hg, diabetes with microalbuminuria, or overt proteinuria
without diabetes). Although not a randomized control
trial, a community education intervention was introduced
that emphasized strategies for reducing obesity and im-
proving diabetic control with ACE inhibitor treatment.
The outcome of this intervention was striking: within
3 years there was measurable benefit in improved blood
pressure control, significant reduction in proteinuria, and
reductions in the incidence of ESRD and overall mortal-
ity [40]. Regrettably, the same investigators now report
evidence of regression of this benefit when funding for
the initiative was not maintained; this outcome demon-
strates the need for a sustained public health commitment
if real and sustained health gains are to be made (Hoy W,
unpublished observations).
In the United States, considerable evidence points to
blacks having inferior access to health care. Blacks report
receiving less information about health care and express
more dissatisfaction with treatment [41]. Fewer black hy-
pertensive patients have their blood pressure checked at
least annually. These differences are reported at all in-
come levels, although blood pressure control might be
more unsatisfactory among blacks living in inner cities
[42]. The only similar study in the United Kingdom shows
a more reassuring trend for earlier referral of blacks with
CKD compared to whites. [43].
Early detection and intervention for preventing or de-
laying CKD are the long-term health goals, but it is also
important that RRT be delivered with equity in ethnic mi-
nority populations. In the United States, mortality in pa-
tients receiving RRT (adjusted for socioeconomic factors
and comorbidity), is consistently lower in ethnic minori-
ties [4]. One single-center study in the United Kingdom
showed no difference in mortality [44], but the United
Kingdom Renal Registry reports a significant reduction
in one-year mortality for blacks on RRT, although no
difference between South Asians and whites (Byrne C
et al, unpublished data). In Hong Kong, survival of Chi-
nese patients undergoing PD is significantly better than
that reported in other large PD studies involving pre-
dominantly white populations [45]. The reasons for these
discrepant outcomes are not clear and require further
study. Ethnicity itself might not be the explanation, and
many other factors might introduce bias. For example,
80% of all dialysis patients in Hong Kong are undergoing
PD compared to the predominance of HD in the United
States. A low patient acceptance also might alter the case
mix; only 54% of Hong Kong Chinese identified as suit-
able for PD agreed to receive the treatment [46]. A low
transplantation rate, as in Hong Kong, also might lead to
younger, fitter patients remaining on PD, thus improving
the cohort outcome.
Data from Leicester show that ethnicity does not in-
fluence the risk that complications from dialysis will
necessitate that patients change to another treatment
modality. Nor does ethnicity affect problems related
to vascular access or hospital admission rates (Carr S,
unpublished observations). However, in Leicester, in
the 1980s non-English–speaking South Asians estab-
lished on CAPD were more likely to switch to HD
because of the consequences of peritonitis (Carr S, un-
published observations). It is reassuring that a range
of improvements in dialysis-related care, including in-
creased language and culture-specific resources, elimi-
nated that inequality in subsequent time periods, and data
from another United Kingdom South Asian population
confirms no difference in infection rate or technique sur-
vival [44]. In a black urban PD population in the United
States, no difference in PD peritonitis was detected
[47].
Registry data from several parts of the world, including
the United Kingdom and the United States, are consistent
in showing inequity of access to renal transplantation or
at least a lower rate of transplantation. Ethnic minority
populations are overrepresented in dialysis programs but
less likely to be listed for cadaveric transplantation, wait
longer, and are less likely to receive allografts (Rudge CJ
et al, unpublished observations). Ethnic minority popu-
lations are under-represented among cadaveric donors so
are more likely to receive poorly matched kidneys. Graft
survival, however, is not inferior in South Asians in the
United Kingdom [48], although it is significantly worse in
blacks in the United States [49]. The most disadvantaged
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of all are patients who do not receive a cadaveric kidney
or a kidney from a live donor.
Promotion of live donor transplantation is a key ele-
ment in strategies for minimizing inequity of access to
transplantation. A study from Baltimore showed that a
decade of active encouragement of volunteerism led to
the same live donor transplant rate in blacks as whites,
with equivalent patient and graft survival, and median
waiting times below the national average [50]. Innova-
tive approaches to live donor transplantation, for exam-
ple, strategies aimed at transplanting across ABO incom-
patibility barriers, also might assume special importance.
United States physicians asked why ethnic minority pa-
tients were referred less frequently for transplantation
most commonly cited the lack of a potential live donor,
patient preference, comorbidity, or concern that patients
did not complete necessary evaluations [51].
In South Asian populations, the high prevalence of
blood group B compared to a majority white donor pop-
ulation with blood group O is a significant limiting factor
in cadaveric transplantation. Haji et al [52] recently pro-
posed that kidneys from A2 donors might be suitable for
B recipients if anti-A antibody titers are low, which ap-
pears to be the case in blood group B South Asians on the
transplant waiting list, unless there is positive panel re-
activity indicating previous sensitization. However, this
strategy has not yet been prospectively tested. Human
leukocyte antigen (HLA) matching algorithms for allo-
cation of cadaveric kidneys disadvantage ethnic minor-
ity populations. A retrospective analysis has investigated
the impact of removing HLA-B matching as a priority for
cadaveric kidney allocation, so that in the absence of a
000 mismatch, the kidney should be allocated on the ba-
sis of DR matching alone. The analysis suggests that this
approach would increase non-white transplants by 6%,
reduce white transplants by 4%, and increase graft loss
by 2% [53].
The shortage of cadaveric donors from ethnic minority
populations is a continuing concern. In the United King-
dom, South Asians and blacks only contribute 1.5% of
the total donor pool yet comprise 6% of the general pop-
ulation and 19% of patients on the cadaveric transplant
waiting list (Rudge CJ, unpublished observations). The
reasons underlying this shortfall have been extensively
explored with these communities, and programs are in
place to improve donor rates through awareness and ed-
ucation, although progress is slow.
Tools for the evaluation of health-related quality of life
are now available for renal disease and have been exten-
sively evaluated. However, these are almost exclusively
written in English, have been developed and tested in
white populations, and might not be sensitive to the cul-
tural, religious, and social distinctions in ethnic minor-
ity populations. Important differences also might emerge
when questionnaire-based quality-of-life assessment re-
lies on the use of health professionals, interpreters, and
family members. These potential biases will not be infre-
quent, even in stable migrant populations, in which older
people do not read or write in English or even in their
native language.
Nevertheless, South Asians in the United Kingdom re-
ported inferior quality of life compared to whites both
on PD and HD, and following renal transplantation [54].
However, health-related quality of life in the Dialysis
Outcomes and Practice Patterns Study (DOPPS) was
higher in ethnic minority patients [55]. The prominence
of religious belief as a coping mechanism has been sug-
gested as a possible explanation for this finding [56]; alter-
natively, in the United States health care setting, a nar-
rowing of the gap in access to good quality health care
after the initiation of RRT might alter perception of qual-
ity of life. There have been no substantial evaluations of
quality of life in ethnic groups in pre-dialysis CKD.
Public health implications
Although exploration of the mechanisms that under-
lie susceptibility to renal disease in these populations is
of the utmost importance for the future, there is a press-
ing worldwide health care challenge that will accelerate
at a pace faster than fundamental research can head off.
In the United Kingdom, the overall age-adjusted relative
risk remains more than threefold in both the South Asian
and African Caribbean populations, and this risk might
be increasing. The younger age distribution of the ethnic
minority population means even larger future increases
in the demand for RRT. Estimates of need are based on
the presumption that current acceptance rates are a true
reflection of demand; this might not be the case if there ex-
ists inequity of access to primary health care or restriction
of referral to renal units. Data from the United Kingdom
Renal Registry show that a higher proportion of South
Asians is referred for nephrology care more than a year
before the initiation of RRT than is the case for African
Caribbeans or whites (Byrne C et al, unpublished data).
Concerns thus remains that late referral (for example,
African Caribbean and low-income whites) is a signifi-
cant factor in a number of poorer and rapidly increasing
migrant populations that are at marked socioeconomic
disadvantage.
Screening for CKD could present fewer organizational
challenges than is sometimes thought. The great major-
ity of patients with CKD will be identified in screening
programs among people with diabetes, hypertension, and
established cardiovascular disease. Thus, an integrated
approach to health care for these populations that share
a high cardiovascular risk with CKD should prove cost-
effective.
The United Kingdom government’s recently published
National Service Framework for Renal Services [57]
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recognizes the increased risk of ESRD among black and
ethnic minority populations, and requires those respon-
sible for health care to meet the needs of these groups
in local planning. But vigorous advocacy must continue
if resources sufficient to deliver the required standards
of care are to be made available where populations in-
clude large ethnic minorities. The very high demand for
RRT must be met. Although intensive efforts at augment-
ing transplantation rates from both cadaveric and live
donors must continue, a disproportionate requirement
for dialysis facilities also will continue. Parallel programs
for screening and early intervention must be introduced
if the future RRT burden is to be restrained. Also, the
delivery of high-quality health care that is linguistically
and culturally adequate for ethnic minorities will likely
require additional resources compared to the resources
needed for majority populations. In other areas of the
world, different strategies might be appropriate, with an
additional emphasis on prevention and early detection,
as provision of universal RRT is economically unrealistic.
Non-government agencies play an important role in
this work, both as advocates promoting public awareness
and government support, and also by generating and di-
recting research resources. One example is the United
Kingdom’s National Kidney Research Fund, which has
been effective in advocacy [58] and, through its ABLE
program (A Better Life through Education and Em-
powerment), also provides resources such as research
programs, investigational models for screening, public
and community awareness, and approaches to the edu-
cation of primary care health professionals. The Interna-
tional Society of Nephrology’s Commission for Global
Advancement of Nephrology (COMGAN) continues to
expand its influence and has been forceful in emphasizing
the pressing needs in nephrologic care in many regions
of the world. Priority also must be given to the long-term
goals of understanding genetic and other factors influ-
encing the susceptibility of ethnic populations to CKD if
truly effective preventative strategies are to be achieved.
QUESTIONS AND ANSWERS
DR. JOHN T. HARRINGTON (Dean Emeritus, Depart-
ment of Medicine, Tufts University School of Medicine;
Division of Nephrology, Tufts-New England Medical Cen-
ter, Boston, Massachusetts): I’ve always been skeptical
about the importance of ethnicity and race per se, al-
though there is no doubt that significant differences exist.
I would argue, as have others [59, 60], that the differences
are largely due to class, which in the United States means
income and other financial assets, and that class exerts
the more powerful effect. How would you respond to
this view?
PROFESSOR FEEHALLY: I would not argue against the
hypothesis that social deprivation is a major health fac-
tor. These articles indicate that in the United States, class
might represent a greater factor than ethnicity as a de-
terminant of health. Some of the other ethnic minority
populations I have discussed are also severely socially
deprived, for example, the native Australian populations
such as the Tiwi, and social deprivation is a feature of
many such indigenous or migrant populations, but it is
not universal. I work in a city that has a migrant South
Asian population that is successful, prosperous, and well
educated. Yet this group has an incidence of ESRD three
to four times that of the white population. Recent reg-
istry data in the United Kingdom also provide evidence
that ethnicity and social deprivation are separate but ad-
ditive influences [36]. In my view, economic deprivation
is not the major causative factor in an increase in kidney
disease, although it might well be an amplifier of both
susceptibility and progression.
DR. HARRINGTON: Are there any data on the health
status of the second generation of South Asians in
Leicester?
PROFESSOR FEEHALLY: Too few second-generation
South Asians born in the United Kingdom have so far
developed ESRD to give us reliable data. However, grow-
ing evidence of type 2 diabetes in South Asians as well as
whites in the United Kingdom underlies a concern that
the incidence of ESRD will increase further.
DR. AMINU K. BELLO (Sheffield Kidney Institute,
Sheffield, United Kingdom): Considering the very high
risk of ESRD among the ethnic minorities, do they re-
quire a different intensity and/or targets of intervention
for better control of risk factors?
PROFESSOR FEEHALLY: We have no evidence that dif-
ferent targets, for example, for glycated hemoglobin or
blood pressure, should be used in ethnic minority popu-
lations; nor that interventions should differ, for example,
the use of ACE inhibitors [39]; nor that the timing of
interventions should differ.
DR. BELLO: Are large-scale epidemiologic studies nec-
essary in sub-Saharan Africa and Asia to corroborate the
research findings here in the west?
PROFESSOR FEEHALLY: Such studies would be very
informative but very difficult to achieve. Studies that use
onset of ESRD for case ascertainment will not give any
information on true prevalence or incidence in countries
where RRT is far from universal, and population-based
epidemiologic studies of CKD require infrastructure and
resources not available in such countries.
DR. AUDREY GOROVICH (York Hospital, York, United
Kingdom): Have you considered other factors that might
influence the incidence of CKD in Asian populations such
as vegetarian diet, traditional herbal remedies, and num-
ber of pregnancies in women?
PROFESSOR FEEHALLY: These are all interesting and
potentially important factors. Diet has not been directly
investigated, but the incidence of ESRD in South Asians
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in the United Kingdom does not appear to differ between
populations that are vegetarian or omnivorous. In view
of the well-known adverse effects of herbal medicine
exemplified by Chinese herb nephropathy, traditional
medicine should be considered, but at present there is
no systematic evidence on this issue. Multiple pregnan-
cies might adversely affect the natural history of ESRD
in women who embark on pregnancy once CKD is es-
tablished, but this has not been systematically studied
either.
DR. GOROVICH: Are any comparisons available with
economically disadvantaged people of white origin in
places like Belarus, Moldavia, or Serbia?
PROFESSOR FEEHALLY: At present, the limited infras-
tructure for the treatment of ESRD in such countries
means that the number of new patients starting RRT is
not a reliable guide to the true incidence of ESRD, so
such comparative information is not available.
DR. ALKIS PIERIDES (Nicosia General Hospital,
Nicosia, Cyprus): The patient you discussed had tubu-
lointerstitial disease with mild hypertension and a rapid
evolution to ESRD. Please comment on the use of nons-
teroidal anti-inflammatory drugs (NSAIDs), which have
been incriminated in part in the increased incidence of
ESRD.
PROFESSOR FEEHALLY: I agree that NSAID use
should be carefully considered when chronic tubuloint-
erstitial disease of otherwise undetermined cause is iden-
tified. But I know of no evidence that they particularly
cause ESRD or its progression in South Asian patients.
DR. PIERIDES: We recently presented data linking mu-
tations 677TT and 677CT/1298AC in the MTHFR gene in
patients with hypertension and a negative urine sediment
to the development of ESRD. It would be a worthwhile
project to investigate mutations in this gene in different
ethnic groups with ESRD.
PROFESSOR FEEHALLY: Yes, thank you for this inter-
esting information. We should consider this among many
other candidate polymorphisms that might influence sus-
ceptibility to renal disease and its progression.
DR. CHARLES PUSEY (Imperial College, London,
United Kingdom): John, you mentioned that many ethnic
populations have an increased incidence of ESRD com-
pared with European whites. I have two related ques-
tions. First, do you think that this increase is due to an
increased prevalence of CKD, or could it be due to a
faster progression to renal failure? The latter is perhaps
suggested by recent data in South Asians from Lightstone
and colleagues (Lightstone L, unpublished observation).
Second, since many ethnic groups across the world appear
to have a higher incidence of ESRD, perhaps we Euro-
pean whites have an unusually low rate. Do you think this
group might have some genetic factor that protects them
from progression and would be amenable to study in our
United Kingdom populations?
PROFESSOR FEEHALLY: We don’t have a definitive an-
swer to your question about faster progression in ethnic
minorities rather than susceptibility to renal disease per
se. But recent data, including that which you mentioned
(Lightstone L, unpublished observations) and data from
the United States, increasingly favor a predominant ef-
fect on progression. It will be important to confirm this
point with further data as soon as possible, because it will
influence our approach not only to etiologic studies (for
example, by restricting the candidate genes we consider)
but also to public health planning of early identification
and intervention.
On your second point, I am increasingly attracted by
the notion that we should reverse our thinking and con-
sider why white populations might be uniquely protected
from ESRD, although this is, of course, rather specula-
tive. And we should not assume that the answer will be a
genetic distinction. For example, the urban, wealthy and
well-fed society in which white Europeans now live has
developed over 200 years or so since the Industrial Revo-
lution, whereas many of the ethnic minority populations
we are considering have been subjected to such urbaniza-
tion and dietary changes over no more than one or two
generations; we could speculate that the rate of environ-
mental change adversely influences the development of
“modern” medical problems, including ESRD.
DR. CHARLIE TOMSON (Institute for Healthcare Im-
provement, Boston, Massachusetts): You described the
excellent outcome of live donor transplantation in this pa-
tient, and this therapy was clearly the right choice. How-
ever, the donor in this case had a family history both of
diabetes and of renal failure. What is your approach to
preoperative counseling of such potential donors?
PROFESSOR FEEHALLY: This is a difficult problem and
one you are right to raise. The donor in this case undoubt-
edly has an increased risk of developing ESRD in later
life. He is South Asian and has a family history of ESRD
and of type 2 diabetes. But at present, we do not have suf-
ficient information to be able to quantify the future risk
of this individual who we know is without clinical renal
disease in young adult life since he has been through a live
donor evaluation. In the absence of such numeric data,
our approach is to rigorously counsel potential donors in
broad terms about the risks. But as we all know, the indi-
vidual desire of the donor and the family dynamics create
a powerful drive toward donation despite such increased
risks.
DR. CHRISTOPHER G. Winearls (Oxford Radcliffe
Hospital, Oxford, United Kingdom): Why are there large
variations in the incidence of ESRD in populations of
European origin, for example, England, North America,
Australia, Belgium, and Germany?
PROFESSOR FEEHALLY: A very important question
and in my view we do not yet properly understand these
differences. It seems improbable that these variations are
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the consequence of major genetic differences or environ-
mental factors, but some interaction of these two, par-
ticularly as it influences susceptibility to type 2 diabetes,
might be important.
DR. GWYN WILLIAMS (Guy’s Hospital, London,
United Kingdom): If we are to achieve our aim of increas-
ing education and awareness about renal disease in ethnic
minority populations, we must convince the United King-
dom and local governments of the importance of the issue
and also involve the local “government” of the National
Health Service, including the hospital Trusts, Foundation
Hospitals and Primary Care Trusts.
PROFESSOR FEEHALLY: I agree it can be a problem en-
gaging National Health Service administrative machinery
to ensure that the issue is given high priority in health
planning. We are particularly fortunate where I work in
Leicester because one Primary Care Trust is responsible
for the health care of a large proportion of our South
Asian population, and the Trust is seriously committed
to these issues. But this is not just an issue for ethnic
minority people at high risk; the need to improve under-
standing of CKD and its early detection and management
affects the entire population. Part 2 of the National Ser-
vice Framework for Renal Services in England (February
2005) will cover these issues and give an important op-
portunity for promoting these matters across the whole
health community.
DR. JEREMY DUFFIELD (Department of Renal
Medicine, Brigham & Womens Hospital, Boston, Mas-
sachusetts): What you have described today is a unifying
model for ESRD in humans, as all causes of renal dis-
ease are over-represented in your South Asian patients. I
would argue strongly that these patients must be enrolled
in a genetic study to identify the key genes regulating pro-
gression.
PROFESSOR FEEHALLY: You will not be surprised to
hear that I agree with you. But such a genetic study is
not entirely straightforward. For example, it is possible
to define a “control” as an individual who at the time
of study has not yet developed CKD, but in a high-risk
population, this does not exclude the possibility that that
individual will do so in the future. Part of the solution
is to make such a study as large as possible. There are
approximately 2500 people of South Asian origin with
ESRD in the United Kingdom at the moment, and we
hope we can secure funding for a DNA bank recruiting
the great majority of the cohort.
DR. LIZ LIGHTSTONE (Imperial College, London,
United Kingdom): I have two comments. First, children
in ethnic communities, especially of consanguinous mar-
riages, have high rates of renal disease, particularly con-
genital structural abnormalities. Second, there are diffi-
culties of access to health care for certain ethnic commu-
nities, including African Caribbeans in the United King-
dom. There might be less clear routes of access to health
care, so management of renal disease in these populations
might be more resistant to community intervention. My
question is whether there is any evidence from mixed-
race populations of dominant protection conferred by
“white” genes?
PROFESSOR FEEHALLY: Thank you for your two im-
portant comments. I agree with you that community in-
terventions will not always be fruitful. One example in
the United Kingdom is the slow progress being made in
increasing cadaveric donor rates among ethnic minority
populations despite some excellent and innovative edu-
cational programs. Access to health care is without doubt
variable, and evidence of late referral is emerging from
some United Kingdom ethnic minority populations. This
problem implies poorer access, for many possible rea-
sons, to specialist renal services [60]. In answer to your
question, I know of no such data among mixed-race pop-
ulations, and I suspect that the major migrations to the
United Kingdom have been too recent for such effects
yet to be identifiable. But I agree with you that this is po-
tentially a very valuable source of genetic information.
DR. HARRINGTON: Neil Powe, an African American
from Washington, DC, who has been interested in these
kinds of studies, presented one of our Forums several
months ago [41]. Dr. Powe has told me that he did not
have any data on the incidence of ESRD in children of
black/white parents. At present neither I nor Dr. Powe is
aware of such studies.
DR. MICHAEL J. World (Queen Elizabeth Hospital,
Birmingham, United Kindom): Gurkha recruits to the
British army must have no evidence of nephritis at en-
listment, but the onset of nephritis was fourfold greater
in Gurkhas than in white male British soldiers from 1985
to 1995 (World M, unpublished observations). No signif-
icant difference was apparent in the proportions of IgA
nephropathy and other types of nephritis between the
Gurkhas and Causasoids. I have the clinical impression
that the rate of deterioration of IgA nephropathy, at least,
is worse in Gurkhas.
PROFESSOR FEEHALLY: That is a very interesting ob-
servation in another population that has not, to my knowl-
edge, been studied previously.
DR. PATRICK NAISH (University Hospital of North
Staffordshire, Stoke-on-Trent, United Kingdom): In light
of the known evidence of the influence of sedentary
lifestyle on type 2 diabetes, the beneficial effect of in-
creased physical activity, and the difficulty of achieving
this change in lifestyle, I would be interested in your com-
ments on this aspect of risk modification.
PROFESSOR FEEHALLY: We know much about exer-
cise, control of energy, and salt intake, all which are im-
portant in these high-risk populations. I am conscious as
a physician of the very small amount of time I have to
influence these issues given the power of advertising, the
food industry, and peer pressure influencing lifestyle. But
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I agree with you that if we can modify lifestyle to the good
and sustain the change for half a century, we will make a
major impact on the issues we are discussing.
DR. TERRY FEEST (Southmead Hospital, Bristol,
United Kingdom): I have two comments. On the question
of prevalence and incidence, if progression is faster, then
patients leave the stage 3 CKD cohort quicker. If pro-
gression is faster in ethnic minorities, and, as you say, the
prevalence of stage 3 CKD is the same in whites and eth-
nic minorities, then the ethnic minorities must be entering
the cohort faster. That is, there must also be a higher inci-
dence as well as faster progression. My second comment
is that in the Renal Association United Kingdom Renal
Registry Report 2003, the effects of social deprivation
and ethnicity were separated. There was a small effect
of social deprivation in whites that was magnified in the
ethnic minorities [36].
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